Trastuzumab plus Chemotherapie bei metastasierendem MagenkarzinomTrastuzumab plus chemotherapy for metastatic gastric cancer

被引：0
|
作者：
K. Schulte
机构：
[1] Kliniken der Stadt Köln gGmbH,Medizinische Klinik
[2] Krankenhaus Holweide,undefined
来源：
Der Gastroenterologe | 2010年 / 5卷 / 6期
关键词：
D O I：
10.1007/s11377-010-0484-y
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：540 / 541
页数：1
相关论文
共 50 条
  • [21] Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients
    Sook Ryun Park
    Myeong-Cherl Kook
    Il Ju Choi
    Chan Gyoo Kim
    Jong Yeul Lee
    Soo-Jeong Cho
    Young-Woo Kim
    Keun Won Ryu
    Jun Ho Lee
    Jong Seok Lee
    Young-Iee Park
    Noe Kyeong Kim
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 579 - 587
  • [22] Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer
    Bian, Li
    Wang, Tao
    Zhang, Shaohua
    Jiang, Zefei
    TUMOR BIOLOGY, 2013, 34 (05) : 3153 - 3158
  • [23] Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients
    Park, Sook Ryun
    Kook, Myeong-Cherl
    Choi, Il Ju
    Kim, Chan Gyoo
    Lee, Jong Yeul
    Cho, Soo-Jeong
    Kim, Young-Woo
    Ryu, Keun Won
    Lee, Jun Ho
    Lee, Jong Seok
    Park, Young-Iee
    Kim, Noe Kyeong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (03) : 579 - 587
  • [24] Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+Metastatic Breast Cancer Patients
    Tolaney, Sara M.
    Goel, Shom
    Nadal, Jorge
    Denys, Hannelore
    Borrego, Manuel R.
    Litchfield, Lacey M.
    Liu, Jiangang
    Appiah, Adams K.
    Chen, Yanyun
    Andre, Fabrice
    CLINICAL CANCER RESEARCH, 2024, 30 (01) : 39 - 49
  • [25] Trastuzumab plus chemotherapy: Convincing survival benefit or not?
    Vogel, CL
    Tan-Chiu, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) : 4247 - 4250
  • [26] Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial
    Kohei Shitara
    Hiroki Hara
    Takaki Yoshikawa
    Kazumasa Fujitani
    Tomohiro Nishina
    Ayumu Hosokawa
    Takashi Asakawa
    Satoe Kawakami
    Kei Muro
    International Journal of Clinical Oncology, 2020, 25 : 301 - 311
  • [27] Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial
    Shitara, Kohei
    Hara, Hiroki
    Yoshikawa, Takaki
    Fujitani, Kazumasa
    Nishina, Tomohiro
    Hosokawa, Ayumu
    Asakawa, Takashi
    Kawakami, Satoe
    Muro, Kei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (02) : 301 - 311
  • [28] Infusion related reactions in the phase 3 SOPHIA trial of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with pretreated HER2+metastatic breast cancer
    Cortes, Javier
    Cardoso, Fatima
    Curigliano, Giuseppe
    Gradishar, William J.
    Im, Seock-Ah
    Rugo, Hope S.
    Bahadur, Shakeela W.
    Falcone, Alfredo
    Murillo, Serafin Morales
    Riseberg, David A.
    Musolino, Antonino
    Feinstein, Trevor M.
    Abreu, Miguel H.
    Im, Young-Hyuck
    Novik, Yelena
    Pluard, Timothy
    Salazar, Lupe G.
    Berardi, Rossana
    Pop, Viorela
    Hong, Shengyan
    Jacobs, Kenneth
    Rock, Edwin
    Pegram, Mark D.
    CANCER RESEARCH, 2021, 81 (04)
  • [29] A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients
    Zhu, Bo
    Wu, Jun-Rong
    Zhou, Xiao-Ping
    MEDICINE, 2015, 94 (34) : e1428
  • [30] Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab
    Nevala-Plagemann, Christopher
    Moser, Justin
    Gilcrease, Glynn Weldon
    Garrido-Laguna, Ignacio
    ESMO OPEN, 2019, 4 (04)
12345